Trial · NCT02781844
Results by group170
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 170
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Time of Maximum Observed Concentration (Cmax) During a Dosing Interval (Tmax) of Baseline Adjusted rhPTH(1-84) | Cohort I: Treatment A | 7.108 | Full Range 0.18 to 14.07 | hours | |
| Time of Maximum Observed Concentration (Cmax) During a Dosing Interval (Tmax) of Baseline Adjusted rhPTH(1-84) | Cohort II: Treatment C | 7.083 | Full Range 0.17 to 13.50 | hours | |
| Time of Maximum Observed Concentration (Cmax) During a Dosing Interval (Tmax) of Baseline Adjusted rhPTH(1-84) | Cohort I+II: Treatment B | 0.333 | Full Range 0.17 to 4.17 | hours | |
| Time of Maximum Observed Concentration (Cmax) During a Dosing Interval (Tmax) of Baseline Adjusted rhPTH(1-84) | Cohort III: Treatment D | 1.000 | Full Range 0.15 to 14.00 | hours | |
| Time of Maximum Observed Concentration (Cmax) During a Dosing Interval (Tmax) of Baseline Adjusted rhPTH(1-84) | Cohort IV: Treatment F | 12.167 | Full Range 0.17 to 13.50 | hours | |
| Time of Maximum Observed Concentration (Cmax) During a Dosing Interval (Tmax) of Baseline Adjusted rhPTH(1-84) | Cohort III + IV: Treatment E | 0.667 | Full Range 0.12 to 4.00 | hours | |
| Maximum Plasma Concentration (Cmax) of Baseline Adjusted rhPTH(1-84) | Cohort I: Treatment A | 136.9 | Geometric Coefficient of Variation 50.9 | picogram per milliliter (pg/mL) | |
| Maximum Plasma Concentration (Cmax) of Baseline Adjusted rhPTH(1-84) | Cohort II: Treatment C | 213.6 | Geometric Coefficient of Variation 51.6 | picogram per milliliter (pg/mL) | |
| Maximum Plasma Concentration (Cmax) of Baseline Adjusted rhPTH(1-84) | Cohort I+II: Treatment B | 339.1 | Geometric Coefficient of Variation 137.8 | picogram per milliliter (pg/mL) | |
| Maximum Plasma Concentration (Cmax) of Baseline Adjusted rhPTH(1-84) | Cohort III: Treatment D | 120.9 | Geometric Coefficient of Variation 83.6 | picogram per milliliter (pg/mL) | |
| Maximum Plasma Concentration (Cmax) of Baseline Adjusted rhPTH(1-84) | Cohort IV: Treatment F | 100.5 | Geometric Coefficient of Variation 106.2 | picogram per milliliter (pg/mL) | |
| Maximum Plasma Concentration (Cmax) of Baseline Adjusted rhPTH(1-84) | Cohort III + IV: Treatment E | 240.8 | Geometric Coefficient of Variation 69.6 | picogram per milliliter (pg/mL) | |
| Area Under the Curve From the Time of Dosing to the Last Measurable Concentration (AUClast) of Baseline Adjusted rhPTH(1-84) | Cohort I: Treatment A | 496.0 | Geometric Coefficient of Variation 34.1 | hour*picogram per milliliter (h*pg/mL) | |
| Area Under the Curve From the Time of Dosing to the Last Measurable Concentration (AUClast) of Baseline Adjusted rhPTH(1-84) | Cohort II: Treatment C | 653.2 | Geometric Coefficient of Variation 25.5 | hour*picogram per milliliter (h*pg/mL) | |
| Area Under the Curve From the Time of Dosing to the Last Measurable Concentration (AUClast) of Baseline Adjusted rhPTH(1-84) | Cohort I+II: Treatment B | 901.1 | Geometric Coefficient of Variation 448.5 | hour*picogram per milliliter (h*pg/mL) | |
| Area Under the Curve From the Time of Dosing to the Last Measurable Concentration (AUClast) of Baseline Adjusted rhPTH(1-84) | Cohort III: Treatment D | 205.0 | Geometric Coefficient of Variation 106.6 | hour*picogram per milliliter (h*pg/mL) | |
| Area Under the Curve From the Time of Dosing to the Last Measurable Concentration (AUClast) of Baseline Adjusted rhPTH(1-84) | Cohort IV: Treatment F | 261.1 | Geometric Coefficient of Variation 77.6 | hour*picogram per milliliter (h*pg/mL) | |
| Area Under the Curve From the Time of Dosing to the Last Measurable Concentration (AUClast) of Baseline Adjusted rhPTH(1-84) | Cohort III + IV: Treatment E | 1044.9 | Geometric Coefficient of Variation 58.0 | hour*picogram per milliliter (h*pg/mL) | |
| Area Under the Curve Extrapolated to Infinity (AUCinf) of Baseline Adjusted rhPTH(1-84) | Cohort I: Treatment A | 484.8 | Geometric Coefficient of Variation 48.4 | h*pg/mL | |
| Area Under the Curve Extrapolated to Infinity (AUCinf) of Baseline Adjusted rhPTH(1-84) | Cohort II: Treatment C | 677.7 | Geometric Coefficient of Variation 22.9 | h*pg/mL |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02781844/results